0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > LAG-3

LAG-3

Brief Information

Name:Lymphocyte activation gene 3 protein
Target Synonym:Lymphocyte activation gene 3 protein,LAG3,Lymphocyte Activating 3,Lymphocyte-Activation Gene 3,CD223 Antigen,Protein FDC,CD223,LAG-3,FDC,sLAG-3
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:29
Lastest Research Phase:Approved

Licensing

Project Name Modality Therapeutic Area Indications Stage Right Available
LAG-3 mAb Monospecific antibody Oncology/Cancer Advanced solid tumor Phase I Global

Product ListCompare or Buy

Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
LA3-M82F3 Mouse Biotinylated Mouse LAG-3 / CD223 Protein, Fc,Avitag™ (MALS verified)
LA3-M82F3-structure
LA3-M82F3-sds
LA3-M5253 Mouse Mouse LAG-3 / CD223 Protein, Fc Tag (MALS verified)
LA3-M5253-structure
LA3-M5253-sds
LA3-H82E9 Human Biotinylated Human LAG-3 / CD223 Protein, His,Avitag™ (MALS verified)
LA3-H82E9-structure
LA3-H82E9-sds
LA3-C8258 Cynomolgus Biotinylated Cynomolgus LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag, ultra sensitivity (primary amine labeling)
LA3-C8258-structure
LA3-C8258-sds
LA3-C52H7 Canine Canine LAG-3 / CD223 Protein, His Tag (MALS verified)
LA3-C52H7-structure
LA3-C52H7-sds
LA3-C82H3 Cynomolgus Cynomolgus LAG-3 / CD223 Protein, His Tag
LA3-C82H3-structure
LA3-C82H3-sds
LA3-C82E5 Cynomolgus Biotinylated Cynomolgus LAG-3 / CD223 Protein, His,Avitag™
LA3-C82E5-structure
LA3-C82E5-sds
LA3-M82E5 Mouse Biotinylated Mouse LAG-3 / CD223 Protein, His,Avitag™ (MALS verified)
LA3-M82E5-structure
LA3-M82E5-sds
LA3-H82Fb Human Biotinylated Human LAG-3 / CD223 Protein, Fc,Avitag™ (MALS verified)
LA3-H82Fb-structure
LA3-H82Fb-sds
LA3-H525c Human Human LAG-3 / CD223 Protein, Llama IgG2b Fc Tag, low endotoxin (MALS verified)
LA3-H525c-structure
LA3-H525c-sds
LA3-H522a Human Human LAG-3 / CD223 Protein, His Tag, low endotoxin
LA3-H522a-structure
LA3-H522a-sds
LA3-H82F3 Human Biotinylated Human LAG-3 / CD223 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
LA3-H82F3-structure
LA3-H82F3-sds
LA3-M52Ha Marmoset Marmoset LAG-3 / CD223 Protein, His Tag
LA3-M52Ha-structure
LA3-M52Ha-sds
LA3-H52Aa Human Human LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag (MALS verified)
LA3-H52Aa-structure
LA3-H52Aa-sds
LA3-C52A0 Cynomolgus Cynomolgus LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag
LA3-C52A0-structure
LA3-C52A0-sds
LA3-C5252 Cynomolgus Cynomolgus LAG-3 / CD223 Protein, Fc Tag
LA3-C5252-structure
LA3-C5252-sds
LA3-H5255 Human Human LAG3 / CD223 Protein, Fc Tag (MALS Verified)
LA3-H5255-structure
LA3-H5255-sds
LA3-M52H5 Mouse Mouse LAG-3 / CD223 Protein, His Tag
LA3-M52H5-structure
LA3-M52H5-sds
LA3-R52H5 Rat Rat LAG3 / CD223 Protein, His Tag
LA3-R52H5-structure
LA3-R52H5-sds
LA3-H5222 Human Human LAG-3 / CD223 Protein, His Tag (MALS verified)
LA3-H5222-structure
LA3-H5222-sds
ACRO Quality

Part of Bioactivity data

LA3-H82F3-Cell-based assay
 LAG-3 FACS

Flow Cytometry assay shows that Biotinylated Human LAG-3, Mouse IgG2a Fc,Avitag (Cat. No. LA3-H82F3) can bind to daudi cell surface. The concentration of LAG-3 used is 0.3 μg/mL (Routinely tested).

LA3-H52Aa-Cell-based assay
 LAG-3 FACS

Flow Cytometry assay shows that Human LAG3, Mouse IgG2a Fc Tag (Cat. No. LA3-H52Aa) can bind to daudi cell surface. The concentration of LAG3 used is 0.3 μg/mL (Routinely tested).

LA3-H5222-SPR
 LAG-3 SPR

Anti-LAG-3 MAb (Human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human LAG-3, His Tag (Cat. No. LA3-H5222) with an affinity constant of 4.57 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

LA3-H5222-BLI
 LAG-3 BLI

Loaded Anti-LAG-3 MAb (Human IgG1) on AHC Biosensor, can bind Human LAG-3, His Tag (Cat. No. LA3-H5222) with an affinity constant of 7.47 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Customer Reviews

Synonym Name

LAG3,CD223,FDC

Background

Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Nivolumab/Relatlimab BMS-986213; BMS-936558/BMS-986016 Approved Bristol-Myers Squibb Company OPDUALAG United States Melanoma Bristol-Myers Squibb Company 2022-03-18 Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Merkel Cell; Colorectal Neoplasms; Melanoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Eftilagimod alpha hLAG-3Ig; CD-223; EDP-202; EOC-202; IMP-321 Phase 3 Clinical Immutep, Prima Biomed Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Neoplasms; Breast Neoplasms; Sarcoma; Peritoneal Neoplasms; Metastatic breast cancer; Melanoma; Carcinoma, Non-Small-Cell Lung Details
INCA-32459 INCA-32459 Phase 1 Clinical Incyte Corp, Merus Nv Neoplasms Details
Ieramilimab IMP-701; LAG-525 Phase 2 Clinical Immutep Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Esophageal adenocarcinoma; Melanoma; Persistent Fetal Circulation Syndrome Details
Bavunalimab XmAb-22841; XmAb-841 Phase 2 Clinical Xencor Inc Cholangiocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Fallopian Tube Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Prostatic Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck Details
Tobemstomig RO-7247669 Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Liver Neoplasms; Carcinoma; Carcinoma, Renal Cell; Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
SHR-1802 SHR-1802 Phase 2 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Solid tumours; Neoplasms Details
FS 118 FS-118 Phase 2 Clinical Merck Serono, F-Star Squamous Cell Carcinoma of Head and Neck; Neoplasms; Neoplasm Metastasis Details
Negalstobart IBI-110 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Small Cell; Melanoma; Carcinoma, Non-Small-Cell Lung Details
KL-A289 KL-A289 Phase 1 Clinical Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, Anyuan Pharmaceutical Technology (Shanghai) Co Ltd Solid tumours Details
DNV-3 DNV3; DNV-3 Phase 2 Clinical Zhejiang Shimai Pharmaceutical Co Ltd Solid tumours; Neoplasms; Skin Neoplasms; Lymphoma Details
Sym-022 Sym-022 Phase 1 Clinical Symphogen A/S Solid tumours; Lymphoma; Neoplasm Metastasis Details
GSK-2831781 IMP-731; GSK‘-781; GSK-2831781; ImmuTune-IMP731 Phase 1 Clinical Prima Biomed Ltd Psoriasis; Colitis, Ulcerative Details
ABL-501 ABL-501 Phase 1 Clinical Abl Bio Inc Solid tumours Details
Tebotelimab PD-1 X LAG-3; MGD-013 Phase 3 Clinical Macrogenics Inc Triple Negative Breast Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Endometrial Neoplasms; Cholangiocarcinoma; Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Liver Neoplasms; Biliary Tract Neoplasms; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms Details
Tuparstobart INCAGN-02385; INCAGN-2385 Phase 2 Clinical Agenus Inc, Incyte Corp Head and Neck Neoplasms; Carcinoma, Merkel Cell; Melanoma Details
HLX-26 HLX-26 Phase 2 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Colorectal Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung Details
MIL-98 MIL-98 Phase 1 Clinical Beijing Mabworks Biotech Co Ltd Solid tumours; Breast Neoplasms; Lymphoma; Melanoma Details
Mavezelimab MK-4280 Phase 2 Clinical Merck Sharp & Dohme Corp Lymphoma, B-Cell; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Hodgkin Disease; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung Details
Mavezelimab/Pembrolizumab MK-4280A; MK-4820A Phase 3 Clinical Msd Ireland (Carlow) Merck Sharp & Dohme Corp, MSD R&D(China)Co Ltd Solid tumours; Carcinoma, Renal Cell; Hodgkin Disease; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Endometrial Neoplasms Details
Miptenalimab BI-754111 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Encelimab TSR-033; TSR 033; TSR033; GSK-4074386 Phase 1 Clinical Anaptysbio Inc Neoplasms Details
GLS-012 GLS-012 Phase 2 Clinical Harbin Gloria Pharmaceuticals Co Ltd Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung Details
LBL-007 LBL-007 Phase 2 Clinical Leads Biolabs Inc, Nanjing Leads Biolabs Co Ltd Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Lymphoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
EMB-02 EMB-02 Phase 2 Clinical Shanghai Epimab Biotherapeutics, Inc Solid tumours Details
AK-129 AK-129 Phase 1 Clinical Zhongshan Akeso Biopharma Co Ltd Neoplasms Details
Fianlimab REGN-3767 Phase 3 Clinical Regeneron Pharmaceuticals Inc Melanoma; Carcinoma, Non-Small-Cell Lung Details
Relatlimab ONO-4482; BMS-986016 Phase 3 Clinical Bristol-Myers Squibb Company Uveal melanoma; Large intestine neoplasm; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular; Melanoma; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Urologic Neoplasms; Gliosarcoma; Colorectal Neoplasms; Sarcoma; Brain Neoplasms; Nasopharyngeal Carcinoma; Chordoma; Solid tumours; Microsatellite instability-high cancer; Multiple Myeloma; Carcinoma, Medullary; Hodgkin Disease; Carcinoma, Transitional Cell; Glioblastoma; Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma; Hematologic Neoplasms Details
IBI-323(Innovent Biologics) IBI-323 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
ZGGS-15 ZGGS15; ZGGS-15 Phase 1 Clinical Suzhou Zelgen Biopharmaceuticals Co Ltd Solid tumours Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken